Estrogen-receptor positive breast cancer

Related records

Broader conditions (17)

• Breast cancer
• Breast carcinoma
• Breast carcinoma by gene expression profile
• Breast disorder
• Breast neoplasm
• Cancer
• Cancer or benign tumor
• Carcinoma
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Human disease
• Neoplasm
• Neoplasm of thorax
• Neoplastic disease or syndrome
• Thoracic cancer

Narrower conditions (2)

• Hormone receptor-positive breast cancer
• Triple-positive breast carcinoma

Trials (27)

• (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
• A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
• A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
• A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
• A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
• A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
• An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients
• Breast Re-irradiation After Second Ipsilateral Lumpectomy
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
• Electronic Medical Record-Based Nudge to Reduce SLNB
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
• Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
• Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
• Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
• Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
• Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Drugs in development (35)

• Abemaciclib Phase 1
• Afimoxifene Phase 2
• Alobresib Phase 1
• Alpelisib Phase 1
• Amcenestrant Phase 2
• Anastrozole Phase 2
• Capecitabine Phase 2
• Crizotinib Phase 2
• Cyclophosphamide Phase 3
• Dalotuzumab Phase 2
• Docetaxel Phase 3
• Doxycycline Phase 2
• Elacestrant Phase 2
• Endoxifen Phase 2
• Enzalutamide Phase 2
• Estetrol Phase 1
• Everolimus Phase 1
• Exemestane Phase 1
• Fulvestrant Phase 2
• Giredestrant Phase 2

Other linked drugs (1)

• Imatinib